Genetics of mineralocorticoid excess: An update for clinicians

European Journal of Endocrinology

Volumn 169, Issue 1, 2013, Pages

  Zennaro, Maria Christina ^a   Jane Rickard, Amanda ^b   Boulkroun, Sheerazed ^c  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALDOSTERONE; ALDOSTERONE SYNTHASE; DEXAMETHASONE; EPLERENONE; GLUCOCORTICOID; MINERALOCORTICOID RECEPTOR; POTASSIUM; POTASSIUM CHANNEL; RENIN; SPIRONOLACTONE;

ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ATP1A1 GENE; ATP2B3 GENE; BLOOD PRESSURE REGULATION; CYP11B1 GENE; CYP11B2 GENE; FAMILIAL DISEASE; FAMILIAL HYPERALDOSTERONISM TYPE I; FAMILIAL HYPERALDOSTERONISM TYPE III; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GROWTH RETARDATION; HERITABILITY; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; KCNJ5 GENE; KCNK9 GENE; LOW DRUG DOSE; NONHUMAN; NR3C2 GENE; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ALDOSTERONE; ANIMALS; DISEASE MODELS, ANIMAL; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MINERALOCORTICOIDS; MUTATION; PLASMA MEMBRANE CALCIUM-TRANSPORTING ATPASES; RENIN; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84879950195     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0813     Document Type: Review

References (83)

1. Connell JM &Davies E. The new biology of aldosterone. Journal of Endocrinology 2005 186 1-20. (doi:10.1677/joe.1.06017)
2. Quinn SJ &Williams GH. Regulation of aldosterone secretion. Annual Review of Physiology 1988 50 409-426. (doi:10.1146/ annurev.ph.50.030188.002205)
3. Newton-Cheh C, Guo CY, Gona P, LarsonMG, Benjamin EJ,Wang TJ, Kathiresan S, O'Donnell CJ, Musone SL, Camargo AL et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007 49 846-856. (doi:10.1161/01.HYP.0000258554.87444.91)
4. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ &Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. New England Journal of Medicine 2004 351 33-41. (doi:10.1056/NEJMoa033263)
5. Meneton P, Galan P, Bertrais S, Heudes D, Hercberg S &Menard J. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations. Journal of Human Hypertension 2008 22 550-558. (doi:10.1038/ jhh.2008.27)
6. Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS, Wilson PW, Rifai N, Meigs JB, Ricken G et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. American Journal of Hypertension 2005 18 657-665. (doi:10.1016/j.amjhyper.2004.12.005)
7. Imrie H, Freel M, Mayosi BM, Davies E, Fraser R, Ingram M, Cordell HJ, Farrall M,Avery PJ,WatkinsHet al. Association between aldosterone production and variation in the 11b-hydroxylase (CYP11B1) gene. Journal of Clinical Endocrinology and Metabolism 2006 91 5051-5056. (doi:10.1210/jc.2006-1481)
8. van Leeuwen N, Caprio M, Blaya C, Fumeron F, Sartorato P, Ronconi V, Giacchetti G, Mantero F, Fernandes-Rosa FL, Simian C et al. The functional c.K2GOC variant of the mineralocorticoid receptor modulates blood pressure, renin, and aldosterone levels. Hypertension 2010 56 995-1002. (doi:10.1161/HYPERTENSIONAHA. 110.155630)
9. Jung J, Barrett PQ, Eckert GJ, Edenberg HJ, Xuei X, Tu W &Pratt JH. Variations in the potassium channel genes KCNK3 and KCNK9 in relation to blood pressure and aldosterone production: an exploratory study. Journal of Clinical Endocrinology and Metabolism 2012 97 2160-2167. (doi:10.1210/jc.2012-2196)
10. Clyne CD, Zhang Y, Slutsker L, Mathis JM,White PC &Rainey WE. Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements. Molecular Endocrinology 1997 11 638-649. (doi:10.1210/me.11.5. 638)
11. White PC &Slutsker L. Haplotype analysis of CYP11B2. Endocrine Research199521437-442. (doi:10.3109/07435809509030459)
12. Bassett MH, Zhang Y, Clyne C,White PC &Rainey WE. Differential regulation of aldosterone synthase and 11b-hydroxylase transcription by steroidogenic factor-1. Journal of Molecular Endocrinology 2002 28 125-135. (doi:10.1677/jme.0.0280125)
13. Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X, Corvol P, Pascoe L &Soubrier F. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998 32 198-204. (doi:10.1161/01.HYP.32.2.198)
14. Casiglia E, Basso G, Guglielmi F, Martini B, Mazza A, Tikhonoff V, Scarpa R, Saugo M, Caffi S &Pessina AC. German origin clusters for high cardiovascular risk in an Italian enclave. International Heart Journal 2005 46 489-500. (doi:10.1536/ihj.46.489)
15. Paillard F, Chansel D, Brand E, Benetos A, Thomas F, Czekalski S, ArdaillouR & Soubrier F. Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension 1999 34 423-429. (doi:10.1161/01.HYP.34.3.423)
16. Davies E, Holloway CD, Ingram MC, Inglis GC, Friel EC, Morrison C, Anderson NH, Fraser R &Connell JM. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999 33 703-707. (doi:10.1161/ 01.HYP.33.2.703)
17. Kupari M, Hautanen A, Lankinen L, Koskinen P, Virolainen J, Nikkila H &White PC. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998 97 569-575. (doi:10.1161/ 01.CIR.97.6.569)
18. McManus F, SandsW, Diver L, MacKenzie SM, Fraser R, Davies E &Connell JM. APEX1 regulation of aldosterone synthase gene transcription is disrupted by a common polymorphism in humans. Circulation Research 2012 111 212-219. (doi:10.1161/CIRCRESAHA. 111.262931) APEX1 regulation of aldosterone synthase gene transcription is disrupted by a common polymorphism in humans
19. Tamaki S, Iwai N, Tsujita Y &Kinoshita M. Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Hypertension 1999 33 266-270. (doi:10.1161/01.HYP.33.1.266)
20. Tsukada K, Ishimitsu T, Teranishi M, Saitoh M, Yoshii M, Inada H, Ohta S, Akashi M, Minami J, Ono H et al. Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension. Journal of Human Hypertension 2002 16 789-793. (doi:10.1038/sj.jhh.1001484)
21. Hautanena A, Lankinen L, Kupari M, Janne OA, Adlercreutz H, Nikkila H & White PC. Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males. Journal of Internal Medicine 1998 244 11-18. (doi:10.1046/ j.1365-2796.1998.00308.x)
22. Lim PO, Macdonald TM, Holloway C, Friel E, Anderson NH, Dow E, Jung RT, Davies E, Fraser R &Connell JM. Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. Journal of Clinical Endocrinology and Metabolism 2002 87 4398-4402. (doi:10.1210/jc.2001-012070)
23. Sookoian S, Gianotti TF, Gonzalez CD &Pirola CJ. Association of the CK344T aldosterone synthase gene variant with essential hypertension: a meta-analysis. Journal of Hypertension 2007 25 5-13. (doi:10.1097/01.hjh. 0000254372.88488.a9)
24. Hannemann A &Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies - a review of the current literature. Hormone and Metabolic Research 2012 44 157-162. (doi:10.1055/s-0031- 1295438)
25. Sutherland DJ, Ruse JL &Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Canadian Medical Association Journal 1966 95 1109-1119.
26. New M. Hypertension of childhood with suppressed renin. Endocrine Reviews 1980 1 421-430. (doi:10.1210/edrv-1-4-421)
27. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S &Lalouel JM. A chimaeric 11b-hydroxylase aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992 355 262-265. (doi:10.1038/ 355262a0)
28. Pascoe L, Jeunemaitre X, Lebrethon MC, Curnow KM, Gomez- Sanchez CE, Gasc JM, Saez JM &Corvol P. Glucocorticoidsuppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. Journal of Clinical Investigation 1995 96 2236-2246. (doi:10.1172/JCI118279)
29. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR &Gordon RD. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. Journal of Clinical Endocrinology and Metabolism 2000 85 3313-3318. (doi:10.1210/jc.85.9.3313)
30. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr &Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 3266-3281. (doi:10. 1210/jc.2008-0104)
31. Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, Schiavone D, Williams TA, Einaudi S, La Grotta A et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino- GENetic forms). Hypertension 2011 58 797-803. (doi:10.1161/ HYPERTENSIONAHA.111.175083)
32. Aglony M, Martinez-Aguayo A, Carvajal CA, Campino C, Garcia H, Bancalari R, Bolte L, Avalos C, Loureiro C, Trejo P et al. Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and biochemical presentation. Hypertension 2011 57 1117-1121. (doi:10.1161/ HYPERTENSIONAHA.110.168740)
33. Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL &Krek AL. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clinical and Experimental Pharmacology &Physiology 1992 19 319-322. (doi:10.1111/ j.1440-1681.1992.tb00462.x)
34. Medeau V, Assie G, Zennaro MC, Clauser E, Plouin PF &Jeunemaitre X. Familial aspect of primary hyperaldosteronism: analysis of families compatible with primary hyperaldosteronism type 2. Annales d'Endocrinologie 2005 66 240-246. (doi:10.1016/ S0003-4266(05)81756-1)
35. Stowasser M &Gordon RD. Familial hyperaldosteronism. Journal of Steroid Biochemistry and Molecular Biology 2001 78 215-229. (doi:10.1016/S0960- 0760(01)00097-8)
36. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL &Krek AL. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clinical and Experimental Pharmacology &Physiology 1991 18 283-286. (doi:10.1111/j.1440-1681.1991.tb01446.x)
37. So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI &Stowasser M. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. Journal of Hypertension 2005 23 1477-1484. (doi:10.1097/01. hjh.0000174299.66369.26)
38. Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, Kelemen L, Jeske Y, Veglio F &Stowasser M. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. Journal of Hypertension 2008 26 1577-1582. (doi:10.1097/HJH. 0b013e3283028352)
39. Davies E, Bonnardeaux A, Plouin PF, Corvol P &Clauser E. Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. Journal of Clinical Endocrinology and Metabolism 1997 82 611-615. (doi:10.1210/ jc.82.2.611)
40. Ballantine DM, Klemm SA, Tunny TJ, Stowasser M &Gordon RD. PCR-SSCP analysis of the promoter region of the renin gene in patients with aldosterone-producing adenomas. Clinical and Experimental Pharmacology &Physiology 1996 23 584-586. (doi:10.1111/j.1440-1681.1996.tb02787.x)
41. Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, Fischer E, Tizzani D, Pallauf A, Viola A et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012 59 235-240. (doi:10.1161/HYPERTENSIONAHA.111.183996)
42. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M &Lifton RP. A novel form of human Mendelian hypertension featuring nonglucocorticoid- remediable aldosteronism. Journal of Clinical Endocrinology and Metabolism 2008 93 3117-3123. (doi:10.1210/jc.2008-0594)
43. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, JiW, Cho Y, Patel A, Men CJ et al. KC channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011 331 768-772. (doi:10.1126/science.1198785)
44. Oki K, PlonczynskiMW, Luis Lam M, Gomez-Sanchez EP &Gomez- Sanchez CE. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology 2012 153 1774-1782. (doi:10.1210/en.2011- 1733)
45. Scholl UI, Nelson-Williams C, Yue P, Grekin R,Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley FL, Farhi A et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. PNAS 2012 109 2533-2538. (doi:10.1073/pnas.1121407109)
46. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, HatchMM,HurtDE, LinL, XekoukiP, Stratakis CAet al.Anovelpoint mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. Journal of Clinical Endocrinology and Metabolism 2012 97 E1532-E1539. (doi:10.1210/jc.2012-1334)
47. Heitzmann D, Derand R, Jungbauer S, Bandulik S, Sterner C, Schweda F, ElWakil A, Lalli E,GuyN,MengualRet al. Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. EMBO Journal 2008 27 179-187. (doi:10.1038/sj.emboj.7601934)
48. Davies LA, Hu C, Guagliardo NA, Sen N, Chen X, Talley EM, Carey RM, Bayliss DA &Barrett PQ. TASK channel deletion in mice causes primary hyperaldosteronism. PNAS 2008 105 2203-2208. (doi:10.1073/pnas.0712000105)
49. Penton D, Bandulik S, Schweda F, Haubs S, Tauber P, Reichold M, Cong LD, El Wakil A, Budde T, Lesage F et al. Task3 potassium channel gene invalidation causes low renin and salt-sensitive arterial hypertension. Endocrinology 2012 153 4740-4748. (doi:10.1210/en.2012-1527)
50. Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, Mulatero P, Samson-Couterie B, Hahner S, Quinkler M et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012 59 592-598. (doi:10.1161/HYPERTENSIONAHA.111.186478)
51. Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S, Brown MJ &O'Shaughnessy KM. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012 59 587-591. (doi:10.1161/HYPERTENSIONAHA.111. 186239)
52. Akerstrom T, Crona J, Delgado Verdugo A, Starker LF, Cupisti K, Willenberg HS, Knoefel WT, Saeger W, Feller A, Ip J et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the kcnj5 potassium channel selectivity filter. PLoS ONE 2012 7 e41926. (doi:10.1371/journal.pone.0041926)
53. Monticone S, Hattangady NG, Nishimoto K, Mantero F, Rubin B, Cicala MV, Pezzani R, Auchus RJ, Ghayee HK, Shibata H et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. Journal of Clinical Endocrinology and Metabolism 2012 97 E1567-E1572. (doi:10.1210/ jc.2011-3132)
54. Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, Shibusawa N, Ozawa A, Okada S, Rokutanda N, Takata D et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. Journal of Clinical Endocrinology and Metabolism 2012 97 1311-1319. (doi:10.1210/ jc.2011-2885)
55. Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosteroneproducing adenomas and secondary hypertension. Nature Genetics 2013 45 440-444. (doi:10.1038/ng.2550)
56. Murthy M, Azizan EA, Brown MJ &O'Shaughnessy KM. Characterization of a novel somatic KCNJ5 mutation delI157 in an aldosterone-producing adenoma. Journal of Hypertension 2012 30 1827-1833. (doi:10.1097/HJH.0b013e328356139f)
57. Hastings MH, Reddy AB &Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nature Reviews. Neuroscience 2003 4 649-661. (doi:10.1038/ nrn1177)
58. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F &Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003 302 255-259. (doi:10.1126/ science.1086271)
59. Kume K, Zylka MJ, Sriram S, Shearman LP, Weaver DR, Jin X, Maywood ES, Hastings MH &Reppert SM. mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell 1999 98 193-205. (doi:10.1016/S0092- 8674(00)81014-4)
60. van der Horst GT, Muijtjens M, Kobayashi K, Takano R, Kanno S, Takao M, de Wit J, Verkerk A, Eker AP, van Leenen D et al. Mammalian Cry1 and Cry2 are essential for maintenance of circadian rhythms. Nature 1999 398 627-630. (doi:10.1038/ 19323)
61. Vitaterna MH, Selby CP, Todo T, Niwa H, Thompson C, Fruechte EM, Hitomi K, Thresher RJ, Ishikawa T, Miyazaki J et al. Differential regulation of mammalian period genes and circadian rhythmicity by cryptochromes 1 and 2. PNAS 1999 96 12114-12119. (doi:10.1073/pnas.96.21.12114)
62. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G, Kanematsu A et al. Salt-sensitive hypertension in circadian clock-deficient Crynull mice involves dysregulated adrenal Hsd3b6. Nature Medicine 2010 16 67-74. (doi:10.1038/nm.2061)
63. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Imamura K, Goto S, Imaizumi K, Hisada Y, Otsuka A et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. Journal of Biological Chemistry 1995 270 18719-18722. (doi:10.1074/jbc.270.32.18719)
64. Le TH, Kim HS, Allen AM, Spurney RF, Smithies O &Coffman TM. Physiological impact of increased expression of the AT1 angiotensin receptor. Hypertension 2003 42 507-514. (doi:10.1161/01.HYP. 0000092000.07559.57)
65. Billet S, Bardin S, Verp S, Baudrie V, Michaud A, Conchon S, Muffat-Joly M, Escoubet B, Souil E, Hamard G et al. Gainof- function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. Journal of Clinical Investigation 2007 117 1914-1925. (doi:10.1172/JCI28764)
66. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME &Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 2005 45 1243-1248. (doi:10.1016/j.jacc.2005.01.015)
67. Freel EM, Mark PB, Weir RA, McQuarrie EP, Allan K, Dargie HJ, McClure JD, Jardine AG, Davies E &Connell JM. Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study. Circulation. Cardiovascular Imaging 2012 5 740-747. (doi:10.1161/CIRCIMAGING.112.974576)
68. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D &Marwick TH. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. Journal of Clinical Endocrinology and Metabolism 2005 90 5070-5076. (doi:10.1210/jc.2005- 0681)
69. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP &Dluhy RG. Intracranial aneurysm and hemorrhagic stroke in glucocorticoidremediable aldosteronism. Hypertension 1998 31 445-450. (doi:10.1161/01.HYP.31.1.445)
70. Wu VC, Chueh SC, Chang HW, Lin LY, Liu KL, Lin YH, Ho YL, Lin WC, Wang SM, Huang KH et al. Association of kidney function with residual hypertension after treatment of aldosteroneproducing adenoma. American Journal of Kidney Diseases 2009 54 665-673. (doi:10.1053/j.ajkd.2009.06.014)
71. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL &Catena C. Long-term renal outcomes in patients with primary aldosteronism. Journal of the American Medical Association 2006 295 2638-2645. (doi:10.1001/jama.295.22.2638)
72. Ribstein J, Du Cailar G, Fesler P &Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. Journal of the American Society of Nephrology 2005 16 1320-1325. (doi:10.1681/ASN. 2004100878)
73. Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A &Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. Journal of Clinical Endocrinology and Metabolism 2009 94 1191-1197. (doi:10.1210/jc.2008- 2245)
74. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney International 2004 66 1-9. (doi:10.1111/ j.1523-1755.2004.00701. x)
75. Utsumi T, Kawamura K, Imamoto T, Nagano H, Tanaka T, Kamiya N, Nihei N, Naya Y, Suzuki H &Ichikawa T. Preoperative masked renal damage in Japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy. International Journal of Urology 2013. In press. (doi:10.1111/iju.12029)
76. Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S &Boscaro M. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. Journal of Hypertension 2007 25 177-186. (doi:10.1097/HJH. 0b013e3280108e6f)
77. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G &Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2006 91 454-459. (doi:10.1210/jc.2005-1733)
78. Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA &Fardella CE. A possible association between primary aldosteronism and a lower b-cell function. Journal of Hypertension 2007 25 2125-2130. (doi:10.1097/HJH.0b013e3282861fa4)
79. Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, Bidlingmaier M, Seissler J &Endres S. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry. Hormone and Metabolic Research 2010 42 435-439. (doi:10.1055/s-0029-1246189)
80. Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X &Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009 53 605-610. (doi:10.1161/HYPERTENSIONAHA. 108.122002)
81. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A &Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. Journal of Clinical Endocrinology and Metabolism 2006 91 3457-3463. (doi:10.1210/jc.2006-0736)
82. Boulkroun S, Golib Dzib JF, Samson-Couterie B, Rosa FL, Rickard AJ, Meatchi T, Amar L, Benecke A &Zennaro MC. KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling. Molecular and Cellular Endocrinology 2013 371 221-227. (doi:10.1016/j.mce.2013. 01.018)
83. Azizan EA, Lam BY, Newhouse SJ, Zhou J, Kuc RE, Clarke J, Happerfield L, Marker A, Hoffman GJ &Brown MJ. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. Journal of Clinical Endocrinology and Metabolism 2012 97 E819-E829. (doi:10.1210/jc.2011-2965) Recherche Médicale